Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Blood·2026

Same author

Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel.

Blood cell therapy·2026

Same author

CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.

Molecular therapy. Oncology·2026

Same author

Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Blood advances·2026

Same author

Immunotherapies for Central Nervous System Tumors and their Neurologic Complications.

Current neurology and neuroscience reports·2026

Same author

Cellular immunotherapies for central nervous system cancers.

Neuro-oncology advances·2025

Search research articles

Related Experiment Video

Updated: Jun 8, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

CAR T-cell therapy for gliomas.

Kun-Wei Song^1,2, Brian J Scott^1,2

¹Department of Neurology, Stanford University School of Medicine.

Current Opinion in Neurology

|November 5, 2024

Summary

This summary is machine-generated.

Chimeric antigen receptor T-cell (CAR T) therapy shows promise for high-grade gliomas, with early trials indicating good tolerability but limited efficacy. Newer CAR T designs aim to improve effectiveness against these challenging brain tumors.

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Jun 8, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Neuro-oncology
Immunotherapy
Cellular Therapy

Background:

High-grade gliomas have a poor prognosis and limited treatment options.
Chimeric antigen receptor T-cell (CAR T) therapy has transformed hematologic malignancy treatment.
Interest is growing in applying CAR T therapy to gliomas.

Purpose of the Study:

To review current CAR T therapy trials for gliomas.
To discuss challenges in CAR T therapy for brain tumors.
To explore future research directions in glioma immunotherapy.

Main Methods:

Review of recently published first-in-human CAR T trials for gliomas.
Analysis of early patient experiences and reported outcomes.
Discussion of evolving CAR T designs and resistance mechanisms.

Main Results:

Early CAR T trials for gliomas demonstrate generally well-tolerated treatment.
Current efficacy of CAR T therapy for gliomas remains limited.
Newer CAR T designs show potential to overcome resistance mechanisms.

Conclusions:

CAR T therapy represents a promising treatment strategy for high-grade gliomas.
Understanding treatment strategies, toxicity, and resistance is crucial for clinical practice and research.
Ongoing clinical trials for CAR T in CNS tumors highlight the need for continued investigation.